Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

Körber, S; Sprute, Katharina; Kratochwil, Clemens; Haefner, MF; Herfarth, Klaus; Kopka, Klaus; Holland‐Letz, Tim; Haberkorn, Uwe; Debus, Jürgen; Giesel, FL

doi:10.1055/s-0040-1708166

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a small retrospective study, 20 patients with BCR after radical prostatectomy and with 3 or fewer oligometastases on PSMA PET/CT were treated with MDT, which postponed the initiation of ADT for 2 y in 74% of patients (69). In another study of 86 patients with recurrent OMPC who were treated with MDT and followed for a median of 26 mo, the 3-y overall survival and biochemical PFS were 84% and 55%, respectively; the median time of ADT-free survival was 13.5 mo (70). In a multicenter FIGURE 1.…”

Section: F-fluciclovinementioning

confidence: 99%

Oligometastatic Prostate Cancer: Current Status and Future Challenges

et al. 2022

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) describe the clinical state of oligometastatic disease along the natural history of prostate cancer; (2) discuss the outcome results of the various clinical trials on metastasis-directed therapy of oligometastatic disease in prostate cancer; and (3) recognize the gaps in knowledge and needed additional areas of research relevant to oligometastatic prostate cancer.

show abstract

Section: F-fluciclovinementioning

confidence: 99%

Oligometastatic Prostate Cancer: Current Status and Future Challenges

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since 2012, when 68 Ga-PSMA-11 has been introduced as a PET tracer, PSMA-ligand PET has emerged as a powerful tool for the detection of tumor recurrences even at low PSA values [23]. Twelve of 24 (50%) studies were on PSMA PET-directed salvage therapy: one randomized clinical trial [7], one prospective [24], and ten retrospective studies [25][26][27][28][29][30][31][32][33][34]. Phillips and colleagues [7] report the outcomes of the phase 2 Observation vs. Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE) clinical trial in patients with hormone-sensitive oligometastatic PC, based on conventional imaging, randomized to receive SBRT versus observation alone.…”

Section: Prostate-specific Membrane Antigenmentioning

confidence: 99%

Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review

Farolfi

Hadaschik

Hamdy

et al. 2021

European Urology Oncology

View full text Add to dashboard Cite

Context: Next-generation imaging includes positron emission tomography (PET) imaging and whole-body magnetic resonance imaging (wbMRI) including diffusion-weighted imaging. Accurate quantification of oligometastatic disease using next-generation imaging is important to define the role and value of metastasisdirected therapy (MDT). Objective: To perform a review of next-generation imaging modalities in the detection of recurrent oligometastatic hormone-sensitive prostate cancer in men who received prior radical treatment for localized disease. Evidence acquisition: MEDLINE, Scopus, Cochrane Libraries, and Web of Science databases were systematically searched for studies reporting next-generation imaging and oncological outcomes. An expert panel of urologists, radiation oncologists, radiologists, and nuclear medicine physicians performed a nonsystematic review of strengths and limitations of currently available imaging options for detecting the presence and extent of recurrent oligometastatic disease. Evidence synthesis: From 370 articles identified, three clinical trials and 21 observational studies met the following inclusion criteria: metachronous oligometastatic recurrence after radical treatment for prostate cancer, MDT, and hormone-sensitive patients. Androgen deprivation therapy (ADT) was allowed before MDT. Next-generation imaging modalities included PET/computed tomography and/or PET/MRI with the following tracers: choline (n = 1), NaF (n = 1), and

show abstract

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

Cited by 2 publications

References 0 publications

Oligometastatic Prostate Cancer: Current Status and Future Challenges

Oligometastatic Prostate Cancer: Current Status and Future Challenges

Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review

Contact Info

Product

Resources

About